CD274 and non-small cell lung carcinoma: In recent years, immunotherapy agents, specifically immune checkpoint inhibitors (ICIs) that target programmed death 1 (PD-1) or its ligand (PD-L1), have shown revolutionary benefits against NSCLC, among other solid tumours [2].